Therefore, mutations and deletions of proteins related to this pathway on tumor cells, such as JAK1 and JAK2, STAT1, and IRF1, the IFNγ receptor chain, can lead to resistance to immune checkpoint inhibitors [18]. Here, IRF1 is linked to neoplasm.